SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a volatile relief rally driven by a combination of a derivatives-led short squeeze and shifting market sentiment regarding U.S.-Iran ceasefire negotiations. The community remains heavily divided, with bulls pointing to institutional accumulation as a foundation for growth while bears dismiss the price action as a temporary trap ahead of potential geopolitical escalation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending as shareholders voice intense frustration over the stock's lack of upward momentum, fueling renewed speculation regarding a potential buyout or urgent partnership deal. The community is actively debating the recent leadership changes in R&D and pressuring activist investor Shah Capital to force a strategic sale, while simultaneously highlighting the persistent suppression of share price by short interest and derivative market mechanics.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently caught in a volatile tug-of-war between institutional accumulation and broader market anxiety surrounding geopolitical tensions and macroeconomic uncertainty. While some traders are focused on bearish technical patterns, many in the community remain bullish, pointing to long-term structural upgrades and the potential for a breakthrough if key resistance levels are reclaimed.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing a massive surge in investor interest driven by a strategic development agreement with Tower Semiconductor, which aims to integrate its high-speed polymer modulators into a silicon photonics platform for AI and data center applications. The community is actively debating the stock's long-term potential as a critical AI infrastructure play versus concerns over its pre-revenue status and historical volatility, with many users focused on whether the current momentum will lead to a broader industry shift or if the stock is vulnerable to a classic pump-and-dump cycle.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is facing intense polarization as it navigates a potential stock split alongside persistent skepticism from short sellers who cite weakening loan performance and broader economic headwinds. The community remains deeply divided, with vocal bears focusing on potential accounting irregularities and valuation concerns, while optimistic traders continue to monitor volatility and institutional positioning for signs of momentum.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

Strategy Inc. (STRC) is trending as investors capitalize on its perpetual preferred series, which offers a double-digit yield and serves as a liquidity engine for aggressive Bitcoin accumulation. While the community is actively debating the sustainability of this 'digital credit' flywheel and its potential impact on Bitcoin price action, many are treating the instrument as a high-yield vehicle to park capital while the company scales its treasury holdings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by escalating geopolitical tensions in the Middle East, specifically the blockage of the Strait of Hormuz and reports of strikes on critical energy infrastructure. Investors are closely monitoring a looming policy deadline and conflicting headlines regarding potential ceasefires, fueling a debate among the community between positioning for a structural oil supply crisis or betting on a rapid de-escalation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community focus as traders debate the company's buyout potential and long-term valuation against larger competitors like Lilly and Novo Nordisk. Investors are actively analyzing recent clinical trial progress and the significant short interest, while weighing the impact of macro-geopolitical pressures on the stock's near-term price volatility.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors debate the impact of ongoing share dilution against the company's aggressive Bitcoin accumulation strategy. The community is sharply divided, with bulls pointing to the potential for a massive short squeeze and long-term Bitcoin appreciation, while bears highlight the high debt levels and persistent underperformance relative to crypto assets.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened volatility and intense community debate as retail traders weigh the impact of potential institutional accumulation against recurring technical resistance. While some investors remain fixated on the prospect of future utility through X-based payment integration and upcoming mining collaborations, others are expressing frustration over stagnant price action and the asset's historical tendency to follow Bitcoins broader downward trends.

statis crypto Watchlist

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX Why This Is New &amp; Significant

- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).

- Category 2B = &quot;useful in certain circumstances&quot; — based on non-randomized data/expert opinion, but still part of the official standard oncologists use daily.

- Expansion beyond CIS — papillary-only (Ta/T1) patients were previously in a gray area or limited to trials/chemo/intravesical options. Now ANKTIVA + BCG is explicitly recommended, which means:

  - More doctors will prescribe it (NCCN is the bible for treatment decisions).

  - Insurance coverage/reimbursement improves dramatically 

This is not FDA approval (that&#39;s the sBLA pending), but NCCN updates are often more impactful for real-world adoption than FDA news because they influence practice patterns and payors faster.

Nick

XRPHomie

JALIB

Dan Knaup

Steve Richer

John Morin

zaltenbairt

Steve call

$IBRX HUGE milestone — NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder cancer patients!

https://x.com/truedat999/status/2033716156943765838?s=48

@blueuefinsashashimi @bullishhbruk HUGE milestone - NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder cancer patients!This expands ANKTIVA to papillary-only cases -...

Groundhog day on X (formerly Twitter): "@blueuefinsashashimi @bullishhbruk HUGE milestone - NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder ...

StockTwits for iOS

ImmunityBio Inc

 Why This Is New & Significant

- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).

- Category 2B = "useful in certain circumstances" — based on non-randomized data/expert opinion, but still part of the official standard oncologists use daily.

- Expansion beyond CIS — papillary-only (Ta/T1) patients were previously in a gray area or limited to trials/chemo/intravesical options. Now ANKTIVA + BCG is explicitly recommended, which means:

  - More doctors will prescribe it (NCCN is the bible for treatment decisions).

  - Insurance coverage/reimbursement improves dramatically 

This is not FDA approval (that's the sBLA pending), but NCCN updates are often more impactful for real-world adoption than FDA news because they influence practice patterns and payors faster.

Kopin Corp

Palantir Technologies Inc

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Cyberlux Corp.

Alzamend Neuro Inc

Spectral AI Inc - Ordinary Shares - Class A

https://x.com/truedat999/status/2033722566242930821?s=48

Why This Is New & Significant today- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).- Category 2B =...

X (Formerly Twitter)

Groundhog day on X (formerly Twitter): "Why This Is New & Significant today- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, inclu...